- Home
- Bonus Reports
- MRTX
Our #1 Biotech Stock For April – Mirati Therapeutics (MRTX)
- Dylan Jovine
- Tuesday, November 1, 2022
Lung cancer is one of the leading causes of cancer-related deaths in the world.
September 2022 Issue: Mirati Therapeutics (SYM: MRTX)
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
October 2020 Issue: Life on Top – Mirati Therapeutics
- Dylan Jovine
- Friday, October 16, 2020
Our #1 Biotech Stock For April – Mirati Therapeutics (MRTX)
- Dylan Jovine
- Tuesday, November 1, 2022
Lung cancer is one of the leading causes of cancer-related deaths in the world.
September 2022 Issue: Mirati Therapeutics (SYM: MRTX)
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
October 2020 Issue: Life on Top – Mirati Therapeutics
- Dylan Jovine
- Friday, October 16, 2020
Categories
Recent posts
Tags
Connect with Us
Get FREE Weekly Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.